NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
NOTE
This title is currently only available in Bookshelf in PDF format (478K). The full-text online version of this publication is forthcoming.
Final
Evidence reviews underpinning recommendations 1.5.1 to 1.5.6 in the NICE guideline
Disclaimer: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.
NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.
Supplemental NICE documents
- Review Evidence review for radioisotope scan: Thyroid cancer: assessment and management: Evidence review C[ 2022]Review Evidence review for radioisotope scan: Thyroid cancer: assessment and management: Evidence review C. 2022 Dec
- Review Evidence review for stimulated or highly sensitive thyroglobulin assays: Thyroid cancer: assessment and management: Evidence review P[ 2022]Review Evidence review for stimulated or highly sensitive thyroglobulin assays: Thyroid cancer: assessment and management: Evidence review P. 2022 Dec
- Evaluation of "solitary" thyroid nodules in a community practice: a managed care approach.[Am J Manag Care. 1998]Evaluation of "solitary" thyroid nodules in a community practice: a managed care approach.Gossain VV, Charnas J, Carella MJ, Rovner DR, Calaca WM. Am J Manag Care. 1998 May; 4(5):679-84.
- Review Evidence review for molecular testing: Thyroid cancer: assessment and management: Evidence review F[ 2022]Review Evidence review for molecular testing: Thyroid cancer: assessment and management: Evidence review F. 2022 Dec
- Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.[Neth J Med. 2016]Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.Hommel I, Pieters GF, Rijnders AJ, van Borren MM, de Boer H. Neth J Med. 2016 May; 74(4):152-7.
- Evidence review for measurement of thyroglobulinEvidence review for measurement of thyroglobulin
Your browsing activity is empty.
Activity recording is turned off.
See more...